Petros Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, manufacture and commercialization of branded and generic pharmaceutical products, over-the-counter products and medical devices. Since its founding in 2015 and subsequent initial public offering in 2021, Petros has pursued an asset-light business model that emphasizes the licensing and acquisition of niche therapy products with established market demand. The company’s portfolio spans prescription and nonprescription offerings, with particular emphasis on dermatology, pain management and gastroenterology.
Headquartered in Holmdel, New Jersey, Petros Pharmaceuticals operates primarily in the United States through strategic partnerships with contract manufacturing organizations and third-party distributors. The company’s product pipeline includes both in-house development candidates and acquired assets, enabling Petros to leverage existing clinical data and regulatory approvals to expedite product launches. Recent additions to its lineup include topical corticosteroids, injectable formulations and pediatric analgesics, further diversifying its therapeutic reach.
Petros’ commercial strategy is built around targeted marketing efforts, specialized sales support and digital engagement platforms designed to drive provider awareness and patient adherence. By focusing on niche indications and leveraging established distribution channels, the company aims to capture market share in crowded therapeutic segments while maintaining an efficient cost structure. In parallel, Petros continues to evaluate acquisition and licensing opportunities that align with its core competencies and growth objectives.
Leadership at Petros Pharmaceuticals is spearheaded by President and Chief Executive Officer Rasool Azimi, whose prior experience in specialty and generics pharmaceuticals informs the company’s disciplined approach to product selection and commercialization. Under Azimi’s guidance, the executive team remains committed to expanding Petros’ product portfolio, strengthening its commercial infrastructure and delivering sustained value to healthcare providers and patients.
AI Generated. May Contain Errors.
